KIHT Gains Government Approval to Conduct Clinical Research for Drugs and Medical Devices in India

For pharma manufacturers evaluating India-based evidence generation, KIHT's newly granted government approval to conduct clinical research for drugs and medical devices marks a concrete expansion of the subcontinent's contract research infrastructure. The authorization positions KIHT as a licensed CRO operating within India's regulated clinical trial framework, adding capacity to a landscape that global sponsors are increasingly scrutinizing for pipeline support.

India's CRO sector has grown steadily under Schedule Y and the broader regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO), which governs clinical trial conduct under provisions aligned with ICH E6 Good Clinical Practice. An institution-level government approval of this kind signals that KIHT has met the requisite standards for site qualification, investigator competency, and ethics committee infrastructure, prerequisites that regulatory affairs leads at multinational sponsors will need to verify independently before trial placement.

The dual scope covering both drugs and medical devices is operationally significant. Device trials carry distinct protocol requirements and post-market surveillance obligations under India's Medical Devices Rules, 2017, and sponsors integrating combination product development will find the expanded mandate relevant when mapping CRO capabilities against study design requirements.

For QA directors and regulatory leads assessing India as a clinical evidence hub, the practical read centres on due diligence: site audits, data integrity controls, and inspection readiness under CDSCO oversight remain sponsor responsibilities regardless of institutional accreditation. KIHT's approval adds a qualified node to the network, but does not transfer the compliance burden.

India's share of global clinical trial activity has been rising, supported by a large treatment-naive patient population, competitive site costs, and progressive alignment of domestic GCP standards with international benchmarks, factors that continue to draw early-phase and bridging study mandates from global manufacturers.

The measurable outcome to track is KIHT's trial activation timeline and its first regulatory submissions to CDSCO following this approval.

Source: Indian Pharma Post via Media4Growth, 11 June 2026.